Jason’s Journey with ALK+ Metatstatic NSCLC

Opinion
Video

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.

  • 34-year-old professional rock climber with ALK+ Stage IV metastatic NSCLC, previously healthy with no smoking history.
  • Persistent lower back pain unresponsive to rest and PT, followed by increased fatigue led to initial doctor visit.
  • CT scan revealed a left lung mass with lymph node involvement and a small metastasis on the spine; molecular testing confirmed ALK-positive status.
  • Started on lorlatinib, with manageable GI issues and fatigue as side effects; patient is motivated to return to climbing.
Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
4 experts in this video
2 experts are featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
4 experts in this video
4 experts in this video
5 experts are featured in this series
Related Content
The trial had an estimated enrollment of 50 patients who received oral TT125-802 as a single agent.

FDA Grants 2 Fast Track Designations to TT125-802 in EGFR/KRAS G12C NSCLC

Tim Cortese
August 28th 2025
Article

TT125-802 monotherapy shrank the tumors in 5 of 7 patients with drug-resistant NSCLC, and no thrombocytopenia was observed.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

First-Line Sacituzumab Tirumotecan Combo Improves Advanced NSCLC Outcomes

First-Line Sacituzumab Tirumotecan Combo Improves Advanced NSCLC Outcomes

Ariana Pelosci
August 21st 2025
Article

The confirmed ORR was 40.0% in cohort 1A and 66.7% in cohort 1B of patients treated with sacituzumab tirumotecan/tagitanlimab for advanced NSCLC.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Findings from the KRYSTAL-12 trial support adagrasib as a treatment option for those with disease progression on prior chemotherapy and immunotherapy.

Adagrasib Boosts PFS, Responses vs Docetaxel in KRAS G12C+ NSCLC

Russ Conroy
August 15th 2025
Article

Findings from the KRYSTAL-12 trial support adagrasib as a treatment option for those with disease progression on prior chemotherapy and immunotherapy.

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Sanan Rasheed, MBBS;Umer Farooq, MBBS;Aiman Waheed, MBBS;Musharaf Khalid Bhutta, MBBS;Adnan Bhat, MD;Hamza Nazir, MBBS;Muhammad Hamza Gul, MBBS, MD;Ayesha Aman, MBBS;Zainab Ibrahim, MBBS;Abdul Baseer Wardak, MBBS
August 14th 2025
Article

Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.